Johns Hopkins University, Baltimore, Maryland, USA.
Top Antivir Med. 2024 Jul 17;32(3):504-510.
Comorbid conditions have a major impact on the health, quality of life, and survival of people with HIV (PWH), particularly as they age. The 2024 Conference on Retroviruses and Opportunistic Infections (CROI) featured many excellent reports related to specific comorbidities, most notably cardiovascular disease, cancer, fatty liver disease, and hypertension. Major themes included hypertension management strategies used in low- and middle-income countries, important insights from the REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) study that focused on cardiometabolic outcomes, studies investigating metabolic-associated fatty liver disease, and the use of glucagon-like peptide-1 receptor agonists in PWH. This review focuses on the abstracts presented at CROI 2024 that discussed these areas, highlighting those with the most clinical impact.
合并症对艾滋病毒感染者（PWH）的健康、生活质量和生存产生重大影响，尤其是随着年龄的增长。2024 年逆转录病毒和机会性感染会议（CROI）上有许多与特定合并症相关的优秀报告，尤其是心血管疾病、癌症、脂肪肝和高血压。主要主题包括中低收入国家使用的高血压管理策略、专注于心血管代谢结果的 REPRIEVE（预防艾滋病毒血管事件的随机试验）研究的重要见解、研究代谢相关脂肪肝的研究以及在 PWH 中使用胰高血糖素样肽-1 受体激动剂。这篇综述重点介绍了在 CROI 2024 上讨论这些领域的摘要，突出了那些具有最临床影响的摘要。
